Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas

BMC Medical Genetics

Janos Geli³  Catharina Larsson³  Tommy Martinsson²  John Inge Johnsen¹  Per Kogner¹  Nimrod B Kiss³ 

[1] Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden;Department of Biosciences, Sahlgrenska University Hospital, Göteborg, Sweden;Center for molecular medicine CMM, Karolinska University Hospital, Stockholm, Sweden

关键词: RASSF2;    RASSF1A;    CDH1;    DCR2;    CASP8;    BLU;    CIMP;    Pyrosequencing;    Neuroblastoma;   

Others  :  1177799
DOI  :  10.1186/1471-2350-13-83

 received in 2012-01-20, accepted in 2012-07-10,  发布年份 2012

【 摘 要 】

Background

In this study we aimed to quantify tumor suppressor gene (TSG) promoter methylation densities levels in primary neuroblastoma tumors and cell lines. A subset of these TSGs is associated with a CpG island methylator phenotype (CIMP) in other tumor types.

Methods

The study panel consisted of 38 primary tumors, 7 established cell lines and 4 healthy references. Promoter methylation was determined by bisulphate Pyrosequencing for 14 TSGs; and LINE-1 repeat element methylation was used as an indicator of global methylation levels.

Results

Overall mean TSG Z-scores were significantly increased in cases with adverse outcome, but were unrelated to global LINE-1 methylation. CIMP with hypermethylation of three or more gene promoters was observed in 6/38 tumors and 7/7 cell lines. Hypermethylation of one or more TSG (comprising TSGs BLU, CASP8, DCR2, CDH1, RASSF1A and RASSF2) was evident in 30/38 tumors. By contrast only very low levels of promoter methylation were recorded for APC, DAPK1, NORE1A, P14, P16, TP73, PTEN and RARB. Similar involvements of methylation instability were revealed between cell line models and neuroblastoma tumors. Separate analysis of two proposed CASP8 regulatory regions revealed frequent and significant involvement of CpG sites between exon 4 and 5, but modest involvement of the exon 1 region.

Conclusions/significance

The results highlight the involvement of TSG methylation instability in neuroblastoma tumors and cell lines using quantitative methods, support the use of DNA methylation analyses as a prognostic tool for this tumor type, and underscore the relevance of developing demethylating therapies for its treatment.

【 授权许可】

   
2012 Kiss et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003, 3(3):203-216.
• [2]Schwab M, Westermann F, Hero B, Berthold F: Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003, 4(8):472-480.
• [3]Larsen WJ, Sherman LS, Potter SS, Scott WJ: Human embryology. London: Livingstone; 1993.
• [4]Mossé YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P: Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008, 455(7215):930-935.
• [5]Carén H, Abel F, Kogner P, Martinsson T: High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 2008, 416(2):152-159.
• [6]Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, Wang L, Soda M, Kikuchi A, Igarashi T: Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008, 455(7215):971-974.
• [7]George RE, Sanda T, Hanna M, Fröhling S, Luther W II, Zhang J, Ahn Y, Zhou W, London WB, McGrady P: Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008, 455(7215):975-978.
• [8]Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, De Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G: Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008, 455(7215):967-970.
• [9]Hoebeeck J, Michels E, Pattyn F, Combaret V, Vermeulen J, Yigit N, Hoyoux C, Laureys G, Paepe AD, Speleman F: Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett 2009, 273(2):336-346.
• [10]Grau E, Martinez F, Orellana C, Canete A, Yañez Y, Oltra S, Noguera R, Hernandez M, Bermúdez JD, Castel V: Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Mol Carcinog 2011, 3:153-162.
• [11]Jones PA, Takai D: The role of DNA methylation in mammalian epigenetics. Science 2001, 293(5532):1068.
• [12]Feinberg AP, Tycko B: The history of cancer epigenetics. Nat Rev Cancer 2004, 4(2):143-153.
• [13]Esteller M: Epigenetics in cancer. N Engl J Med 2008, 358(11):1148-1159.
• [14]Baylin SB: Mechanisms underlying epigenetically mediated gene silencing in cancer. Semin Cancer Biol 2002, 12(5):331-337.
• [15]Teodoridis JM, Hardie C, Brown R: CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett 2008, 268(2):177-186.
• [16]Issa JP: CpG island methylator phenotype in cancer. Nat Rev Cancer 2004, 4(12):988-993.
• [17]Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y, Takato T, Nakagawara A, Ushijima T: CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 2005, 65(3):828.
• [18]Abe M, Westermann F, Nakagawara A, Takato T, Schwab M, Ushijima T: Marked and independent prognostic significance of the CpG island methylator phenotype in neuroblastomas. Cancer Lett 2007, 247(2):253-258.
• [19]Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JPJ: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci 1999, 96(15):8681.
• [20]Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301(5895):89-92.
• [21]Belgnaoui SM, Gosden R, Semmes OJ, Haoudi A: Human LINE-1 retrotransposon induces DNA damage and apoptosis in cancer cells. Cancer Cell Int 2006, 6(1):13. BioMed Central Full Text
• [22]Yang AS, Estécio MRH, Doshi K, Kondo Y, Tajara EH, Issa JPJ: A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004, 32(3):e38-e38.
• [23]Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, Ehrlich M, Laird PW: Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 2005, 33(21):6823.
• [24]Hata K, Sakaki Y: Identification of critical CpG sites for repression of L1 transcription by DNA methylation. Gene 1997, 189(2):227-234.
• [25]Takai D, Yagi Y, Habib N, Sugimura T, Ushijima T: Hypomethylation of LINE1 retrotransposon in human hepatocellular carcinomas, but not in surrounding liver cirrhosis. Jpn J Clin Oncol 2000, 30(7):306-309.
• [26]Choi IS, Estecio MRH, Nagano Y, Kim DH, White JA, Yao JC, Issa JPJ, Rashid A: Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors (pancreatic endocrine tumors and carcinoid tumors). Mod Pathol 2007, 20(7):802-810.
• [27]Ogino S, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS: LINE‐1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 2008, 122(12):2767-2773.
• [28]Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ: Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000, 6(5):529-535.
• [29]Banelli B, Casciano I, Croce M, Di Vinci A, Gelvi I, Pagnan G, Brignole C, Allemanni G, Ferrini S, Ponzoni M: Expression and methylation of CASP8 in neuroblastoma: identification of a promoter region. Nat Med 2002, 8(12):1333-1335.
• [30]Jeison M, Yaniv I, Ash S: Genetic stratification of neuroblastoma for treatment tailoring. Future Oncol 2011, 7(9):1087-1099.
• [31]Mueller S, Matthay KK: Neuroblastoma: biology and staging. Curr Oncol Rep 2009, 11(6):431-438.
• [32]Geli J, Kiss N, Karimi M, Lee JJ, Bäckdahl M, Ekström TJ, Larsson C: Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior. Clin Cancer Res 2008, 14(9):2551-2559.
• [33]Nakagawara A: Neural crest development and neuroblastoma: the genetic and biological link. Prog Brain Res 2004, 146:231-242.
• [34]Carén H, Djos A, Nethander M, Sjöberg RM, Kogner P, Enström C, Nilsson S, Martinsson T: Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer 2011, 11(1):66. BioMed Central Full Text
• [35]Aggerholm A, Hokland P, Guldberg P: DAP-kinase CpG island methylation in acute myeloid leukemia: methodology versus biology? Blood 2000, 95(9):2997-2999.
• [36]Rand K, Qu W, Ho T, Clark SJ, Molloy P: Conversion-specific detection of DNA methylation using real-time polymerase chain reaction (ConLight-MSP) to avoid false positives. Methods 2002, 27(2):114-120.
• [37]Strasser A, Jost PJ, Nagata S: The many roles of FAS receptor signaling in the immune system. Immunity 2009, 30(2):180-192.
• [38]Gonzalez-Gomez P, Bello M, Lomas J, Arjona D, Alonso M, Aminoso C, Lopez-Marin I, Anselmo N, Sarasa J, Gutierrez M: Aberrant methylation of multiple genes in neuroblastic tumours: relationship with MYCN amplification and allelic status at 1p. Eur J Cancer 2003, 39(10):1478-1485.
• [39]Fulda S, Poremba C, Berwanger B, Häcker S, Eilers M, Christiansen H, Hero B, Debatin KM: Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma. Cancer Res 2006, 66(20):10016.
• [40]Symer DE, Connelly C, Szak ST, Caputo EM, Cost GJ, Parmigiani G, Boeke JD: Human L1 retrotransposition is associated with genetic instability in vivo. Cell 2002, 110(3):327-338.
• [41]Misawa A, Tanaka S, Yagyu S, Tsuchiya K, Iehara T, Sugimoto T, Hosoi H: RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker. Br J Cancer 2009, 100(2):399-404.
• [42]Yagyu S, Gotoh T, Iehara T, Miyachi M, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, Tamura S, Tsuchiya K, Imamura T: Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma. Clin Cancer Res 2008, 14(21):7011-7019.
• [43]Johnsen J, Segerström L, Orrego A, Elfman L, Henriksson M, Kågedal B, Eksborg S, Sveinbjörnsson B, Kogner P: Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 2007, 27(20):2910-2922.
• [44]Geli J, Kogner P, Lanner F, Natalishvili N, Juhlin C, Kiss N, Clark GJ, Ekström TJ, Farnebo F, Larsson C: Assessment of NORE1A as a putative tumor suppressor in human neuroblastoma. Int J Cancer 2008, 123(2):389-394.
• [45]Geli J, Kiss N, Kogner P, Larsson C: Suppression of RIZ in biologically unfavourable neuroblastomas. Int J Oncol 2010, 37(5):1323-1330.